ATHE
Alterity Therapeutics Limited
NASDAQ · Healthcare · Biotechnology · AU
$4.54
+0.44%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.8x
Market Cap
$82.67M
MomentumView details →
1D Return
+0.44%
YTD Return
+44.81%
RSI (14)
45.5
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.8x
Market Cap
$82.67M
RSI (14)
45.5
MomentumView details →
1D Return
+0.44%
YTD Return
+44.81%
SummaryUpdated Jun 1, 2026
Alterity Therapeutics Limited (ASX:ATHE) is an Australian biotechnology company founded in 1997 and headquartered in Melbourne. Originally incorporated as Prana Biotechnology Limited, the company rebranded to its current name in April 2019. Alterity focuses on developing therapeutic drugs to treat neurodegenerative diseases, particularly Alzheimer's disease, Huntington's disease, Parkinson's disease, and other neurological disorders. As a clinical-stage biotechnology company, Alterity has been publicly traded since 2003 and represents the emerging field of precision medicine targeting neurodegeneration through novel therapeutic approaches.
Similar companies
Latest newsMore news →
Alterity Therapeutics announced the granting of a new U.S. composition of matter patent for its drug candidate ATH434, extending protection to at least 2045.23d agoAlterity Therapeutics received FDA End-of-Phase 2 meeting minutes confirming the registrational pathway for ATH434 in Multiple System Atrophy.59d agoAlterity Therapeutics achieved alignment with the U.S. FDA on the pivotal Phase 3 program for ATH434 in Multiple System Atrophy.87d ago